Published in J Neurosci Res on March 01, 2008
Dynamic instability of microtubule growth. Nature (1984) 20.32
The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem (1977) 11.55
Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell (1978) 5.16
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 4.34
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience (1991) 4.05
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry (2001) 3.20
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry (2004) 2.57
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry (1998) 2.30
Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry (1992) 2.21
Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci (1998) 1.86
Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry (1996) 1.85
Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res (1998) 1.76
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev (1993) 1.74
Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry (1984) 1.63
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Neuropsychopharmacology (1999) 1.50
Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev (2003) 1.43
Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry (1998) 1.38
Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry (2000) 1.34
Secretory trafficking in neuronal dendrites. Nat Cell Biol (2004) 1.32
Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev (2004) 1.28
Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry (1991) 1.27
STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res (2005) 1.23
The synaptic hypothesis of schizophrenia. Neuron (2003) 1.21
Cognitive basis of hallucinations in schizophrenia: role of top-down information processing. Schizophr Res (2003) 1.20
Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry (1992) 1.17
Role of adenosine in sleep and temperature regulation in the preoptic area of rats. Pharmacol Biochem Behav (1991) 1.16
Impaired olfactory identification in relatives of patients with familial schizophrenia. Am J Psychiatry (2001) 1.13
Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr Res (2006) 1.13
Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry (2003) 1.11
Long-lasting insomnia induced by preoptic neuron lesions and its transient reversal by muscimol injection into the posterior hypothalamus in the cat. Neuroscience (1989) 1.08
STOP proteins are responsible for the high degree of microtubule stabilization observed in neuronal cells. J Cell Biol (1998) 1.08
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
Cloning, expression, and properties of the microtubule-stabilizing protein STOP. Proc Natl Acad Sci U S A (1996) 1.07
The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev (2002) 1.06
Dopaminergic transmission in STOP null mice. J Neurochem (2005) 1.06
Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry (2006) 1.01
Tau confers drug stability but not cold stability to microtubules in living cells. J Cell Sci (1994) 1.01
Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology (2004) 1.01
STOP proteins. Biochemistry (2003) 0.99
Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med (1997) 0.98
Olfactory impairment in monozygotic twins discordant for schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 0.97
Ratings of different olfactory judgements in schizophrenia. Chem Senses (2002) 0.96
Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res (2006) 0.95
Nonneuronal isoforms of STOP protein are responsible for microtubule cold stability in mammalian fibroblasts. Proc Natl Acad Sci U S A (1998) 0.92
Dopamine D2 densities and the schizophrenic brain. Schizophr Res (1998) 0.91
Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse (1999) 0.91
Astrocytes and oligodendrocytes express different STOP protein isoforms. J Neurosci Res (2004) 0.90
Phosphorylation of microtubule-associated protein STOP by calmodulin kinase II. J Biol Chem (2006) 0.89
Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol (2006) 0.88
Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia. J Neurosci Res (2007) 0.87
STOP-like protein 21 is a novel member of the STOP family, revealing a Golgi localization of STOP proteins. J Biol Chem (2006) 0.87
Clinical symptoms and regional cerebral blood flow in schizophrenia. Eur Arch Psychiatry Clin Neurosci (1995) 0.85
Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res (1993) 0.84
Ambient temperature-dependence of sleep disturbances produced by basal forebrain damage in rats. Brain Res Bull (1984) 0.84
Effects of acute administration of caffeine on local cerebral glucose utilization in the rat. Eur J Pharmacol (1984) 0.84
Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Res (1999) 0.83
Local cerebral glucose utilization in normal female rats: variations during the estrous cycle and comparison with males. J Cereb Blood Flow Metab (1985) 0.81
Local cerebral glucose utilization in the free moving mouse: a comparison during two stages of the activity-rest cycle. Brain Res (1985) 0.81
Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain. J Neurosci Res (2007) 0.80
Mapping of the progressive metabolic changes occurring during the development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy. Brain Res (2000) 0.80
Microtubule-associated protein MAP2 expression in olfactory bulb in schizophrenia. Psychiatry Res (2004) 0.79
Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. Psychol Med (1993) 0.79
Reversibility of hemodynamic hypofrontality in schizophrenia. J Cereb Blood Flow Metab (1987) 0.78
BMS-310705 Bristol-Myers Squibb/GBF. Curr Opin Investig Drugs (2004) 0.77
Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can J Psychiatry (2001) 0.77
Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharmacol (2005) 0.77
Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol (2006) 2.25
Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat Genet (2013) 2.06
From the editors: Epilepsia's survey on the necessity of the Wada test and intracranial electrodes for cortical mapping. Epilepsia (2014) 2.02
MCAK associates with the tips of polymerizing microtubules. J Cell Biol (2005) 1.92
A family of protein-deglutamylating enzymes associated with neurodegeneration. Cell (2010) 1.77
A vital role of tubulin-tyrosine-ligase for neuronal organization. Proc Natl Acad Sci U S A (2005) 1.70
Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J Physiol (2004) 1.66
Predictive value of cortical injury for the development of temporal lobe epilepsy in 21-day-old rats: an MRI approach using the lithium-pilocarpine model. Epilepsia (2002) 1.62
Motor-dependent microtubule disassembly driven by tubulin tyrosination. J Cell Biol (2009) 1.49
Should consciousness describe seizures and what terms should be applied? Epilepsia's survey results. Epilepsia (2014) 1.42
Developmental characteristics of picrotoxin-induced convulsions in rats with genetic absence epilepsy. Exp Neurol (2003) 1.41
Reasons for discrepancy between incidence and prevalence of epilepsy in lower income countries: Epilepsia's survey results. Epilepsia (2014) 1.38
STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res (2005) 1.23
Magnetic resonance imaging in the study of the lithium-pilocarpine model of temporal lobe epilepsy in adult rats. Epilepsia (2002) 1.21
Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem Int (2006) 1.20
Epilepsy biomarkers. Epilepsia (2013) 1.19
NIRS-measured oxy- and deoxyhemoglobin changes associated with EEG spike-and-wave discharges in children. Epilepsia (2008) 1.13
Models of pediatric epilepsies: strategies and opportunities. Epilepsia (2006) 1.12
A 5-month period of epilepsy impairs spatial memory, decreases anxiety, but spares object recognition in the lithium-pilocarpine model in adult rats. Epilepsia (2005) 1.10
Post-translational arginylation of calreticulin: a new isospecies of calreticulin component of stress granules. J Biol Chem (2006) 1.09
Triadin deletion induces impaired skeletal muscle function. J Biol Chem (2009) 1.09
Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol (2004) 1.08
A new role for kinesin-directed transport of Bik1p (CLIP-170) in Saccharomyces cerevisiae. J Cell Sci (2008) 1.08
Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol Dis (2004) 1.07
The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev (2002) 1.06
Dopaminergic transmission in STOP null mice. J Neurochem (2005) 1.06
Depolarizing actions of GABA in immature neurons depend neither on ketone bodies nor on pyruvate. J Neurosci (2011) 1.05
Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia (2007) 1.03
Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry (2006) 1.01
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia (2012) 1.01
Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission. J Neurochem (2008) 1.00
A robust statistics-based global energy function for the alignment of serially acquired autoradiographic sections. J Neurosci Methods (2003) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
STOP proteins. Biochemistry (2003) 0.99
Decreased expression of glutamate transporters in genetic absence epilepsy rats before seizure occurrence. J Neurochem (2002) 0.98
Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol (2009) 0.98
The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances. J Neurochem (2012) 0.97
Cellular disorders induced by high magnetic fields. J Magn Reson Imaging (2005) 0.96
The deletion of the microtubule-associated STOP protein affects the serotonergic mouse brain network. J Neurochem (2010) 0.96
Evidence for an intracellular ADP-ribosyl cyclase/NAD+-glycohydrolase in brain from CD38-deficient mice. J Biol Chem (2003) 0.96
Metabolism is normal in astrocytes in chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. J Cereb Blood Flow Metab (2005) 0.95
Tubulin tyrosination is required for the proper organization and pathfinding of the growth cone. PLoS One (2009) 0.95
Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci (2007) 0.92
Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia (2007) 0.92
The involvement of limbic structures in typical and atypical absence epilepsy. Epilepsy Res (2012) 0.92
Cacnb4 directly couples electrical activity to gene expression, a process defective in juvenile epilepsy. EMBO J (2012) 0.91
Issues related to development of antiepileptogenic therapies. Epilepsia (2013) 0.91
Phosphorylation of microtubule-associated protein STOP by calmodulin kinase II. J Biol Chem (2006) 0.89
Local cerebral blood flow during lithium-pilocarpine seizures in the developing and adult rat: role of coupling between blood flow and metabolism in the genesis of neuronal damage. J Cereb Blood Flow Metab (2002) 0.89
Prion protein expression and functional importance in developmental angiogenesis: role in oxidative stress and copper homeostasis. Antioxid Redox Signal (2012) 0.89
Prolonged refractory status epilepticus with early and persistent restricted hippocampal signal MRI abnormality. J Neurol (2008) 0.89
Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia (2013) 0.88
Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol (2006) 0.88
Epilepsy and neuroprotection: an illustrated review. Epileptic Disord (2002) 0.88
Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia. J Neurosci Res (2007) 0.87
Excitatory action of GABA on immature neurons is not due to absence of ketone bodies metabolites or other energy substrates. Epilepsia (2011) 0.87
Ketogenic diet exhibits neuroprotective effects in hippocampus but fails to prevent epileptogenesis in the lithium-pilocarpine model of mesial temporal lobe epilepsy in adult rats. Epilepsia (2010) 0.87
STOP-like protein 21 is a novel member of the STOP family, revealing a Golgi localization of STOP proteins. J Biol Chem (2006) 0.87
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
Astrocytes may play a role in the etiology of absence epilepsy: a comparison between immature GAERS not yet expressing seizures and adults. Neurobiol Dis (2007) 0.86
How morphological constraints affect axonal polarity in mouse neurons. PLoS One (2012) 0.86
NIRS-measured oxy- and deoxyhemoglobin changes associated with EEG spike-and-wave discharges in a genetic model of absence epilepsy: the GAERS. Epilepsia (2010) 0.85
Inflammation in rat pups subjected to short hyperthermic seizures enhances brain long-term excitability. Epilepsy Res (2009) 0.85
Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia (2014) 0.85
CD38-dependent ADP-ribosyl cyclase activity in developing and adult mouse brain. Biochem J (2003) 0.85
Attention and executive functions in a rat model of chronic epilepsy. Epilepsia (2014) 0.85
Cortical glutamate metabolism is enhanced in a genetic model of absence epilepsy. J Cereb Blood Flow Metab (2006) 0.84
Bmcc1s, a novel brain-isoform of Bmcc1, affects cell morphology by regulating MAP6/STOP functions. PLoS One (2012) 0.84
Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology (Berl) (2009) 0.84
Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology (2007) 0.84
MAP6-F is a temperature sensor that directly binds to and protects microtubules from cold-induced depolymerization. J Biol Chem (2012) 0.83
In the lithium-pilocarpine model of epilepsy, brain lesions are not linked to changes in blood-brain barrier permeability: an autoradiographic study in adult and developing rats. Exp Neurol (2003) 0.83
Cannabidiol and medical marijuana for the treatment of epilepsy. Epilepsia (2014) 0.82
Consequences of pilocarpine-induced status epilepticus in immunodeficient mice. Brain Res (2012) 0.81
Time course and mapping of cerebral perfusion during amygdala secondarily generalized seizures. Epilepsia (2005) 0.81
Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia (2003) 0.81
A comprehensive behavioral evaluation in the lithium-pilocarpine model in rats: effects of carisbamate administration during status epilepticus. Epilepsia (2013) 0.81
Overlap of promoter and coding sequences in the mouse STOP gene (Mtap6). Genomics (2003) 0.81